Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity

BET bromodomain inhibitors hold promise as therapeutic agents in diverse indications, but their clinical progression has been challenging and none have received regulatory approval. Early clinical trials in cancer have shown heterogeneous clinical responses, development of resistance, and adverse ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Estoppey, David, Schutzius, Gabi, Kolter, Christian, Salathe, Adrian, Wunderlin, Tiffany, Meyer, Amandine, Nigsch, Florian, Bouwmeester, Tewis, Hoepfner, Dominic, Kirkland, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581576/
https://www.ncbi.nlm.nih.gov/pubmed/34805786
http://dx.doi.org/10.1016/j.isci.2021.103323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581576/
https://www.ncbi.nlm.nih.gov/pubmed/34805786
http://dx.doi.org/10.1016/j.isci.2021.103323

Ejemplares similares